Home>Topics>Companies>Ranbaxy Laboratories

Ranbaxy Laboratories

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. UPDATE 3- Ranbaxy pleads guilty, to pay $500 mln in US settlement

    Headlines

    Mon, 13 May 2013

    May 13 (Reuters) - Indian generic drugmaker Ranbaxy Laboratories Ltd pleaded guilty on Monday to felony charges related to drug safety and will pay $500 million in civil and criminal fines under the settlement agreement with the U.S. Department of Justice.

  2. Indian drugmaker Ranbaxy to pay $500 mln in U.S. DOJ settlement

    Headlines

    Mon, 13 May 2013

    May 13 (Reuters) - Indian drugmaker Ranbaxy Laboratories Ltd pleaded guilty on Monday to felony charges related to drug safety and will pay $500 million in civil and criminal fines under the settlement agreement with the U.S. Department of Justice.

  3. BRIEF- Ranbaxy pleads guilty to felony charges over drugs, to pay $500 mln in U.S. settlement

    Headlines

    Mon, 13 May 2013

    May 13 (Reuters) - Ranbaxy Laboratories Ltd : * U.S. Justice Department says Ranbaxy Laboratories Ltd unit pleads

  4. India's Ranbaxy Q1 net profit plunges, lags estimates

    Headlines

    Wed, 8 May 2013

    MUMBAI, May 8 (Reuters) - Ranbaxy Laboratories , India's largest drugmaker by sales, reported a 90 percent drop in first quarter net profit compared to the same year-ago

  5. Cipher Pharma Continues To Deliver

    Headlines

    Mon, 6 May 2013

    Absorica (CIP-Isotretinoin) at Ranbaxy ( RBXLY.OB ), and continued growth ..... transfer pricing on U.S. sales at Ranbaxy . We note that Cipher receives a ..... royalty on U.S. sales of Absorica at Ranbaxy , meaning that sales in the first

  6. Asian Stocks Pull Back After Solid Start

    Headlines

    Fri, 29 Mar 2013

    Astellas Pharma registered a quarterly gain of 30.58%, while Daiichi Sankyo Co. Ltd is up 36.91%. India's Lupin Ltd. is up a modest 2.4% but Ranbaxy Laboratories RBXD slumped 13.11%. Among exporters, Tokyo-listed car manufacturer

  7. This Little-Known Stock Could Double Thanks To The 'Patent Cliff'

    Headlines

    Wed, 6 Mar 2013

    its crown jewel, sales of Lipitor fell by 50% the first week it went off patent in late December 2011. But for Ranbaxy Laboratories , it was a watershed moment, reaping $500 million in sales for its generic version of Lipitor in just the first

  8. UPDATE 1-India's Ranbaxy surprises with Q4 loss, sees modest sales growth in 2013

    Headlines

    Tue, 26 Feb 2013

    MUMBAI, Feb 26 (Reuters) - Ranbaxy Laboratories Ltd , India's top drugmaker by sales, said its base business would grow a modest 10 percent in 2013 after reporting a surprise quarterly loss on product recall charges, sending its shares down more than 4 percent.

  9. India's Ranbaxy reports Q4 loss on provision for product recall, forex

    Headlines

    Tue, 26 Feb 2013

    MUMBAI, Feb 26 (Reuters) - Ranbaxy Laboratories Ltd , India's top drugmaker by sales, reported a quarterly net loss of 4.92 billion rupees ($91.30 million) after setting

  10. Ranbaxy to resume generic Lipitor production for U.S.

    Headlines

    Fri, 22 Feb 2013

    Feb 22 (Reuters) - Indian generic drugmaker Ranbaxy Laboratories Ltd said on Friday it will resume production of its version ..... resolving the issues that led to a November recall. Ranbaxy in November recalled its atorvastatin from the U

« Prev12345Next »
Content Partners